Fig. 1.

Pharmacologic targeting of FXI with 14E11 attenuates EAE symptoms. Male C57BL/6 mice immunized with MOG/CFA/Ptx were monitored and assigned a disease score daily. At peak disease onset (disease score ≥ 2.5), mAb 14E11 (1 mg/kg, i.v.) was administered every other day for four days (a). The mean disease scores (b) and the cumulative disease index (c) for 14E11-treated mice were significantly lower compared to mice treated with vehicle. Data are presented as mean ± SEM for two independent experiments, where n = 7–9. Statistical analyses were performed using Mann-Whitney tests on GraphPad Prism 9. Statistical significance is indicated by a single asterisk (*) for P ≤ 0.05